Product image of Myfortic (Mycophenolic Acid) supplied by GNH India

Myfortic

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release oral tablet for oral use. It prevents organ transplant rejection in adult patients receiving solid‑organ grafts.

GNH India supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Novartis Healthcare A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myfortic, an antimetabolite immunosuppressant, is used in solid‑organ transplantation to reduce immune‑mediated graft rejection.

  • Kidney transplant: lowers the risk of acute and chronic rejection.
  • Heart transplant: helps maintain graft function by suppressing lymphocyte proliferation.
  • Liver transplant: supports long‑term graft survival through immune modulation.

How It Works

  • Myfortic delivers mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This enzyme blockade reduces guanosine nucleotide synthesis, a critical pathway for lymphocyte proliferation, thereby dampening the adaptive immune response that drives organ‑rejection processes.

Side Effects

Myfortic may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: watery stools often occurring early in therapy.
  • Abdominal pain: cramping or discomfort in the stomach area.
  • Headache: transient tension‑type headaches.
  • Tremor: fine shaking of the hands or limbs.
  • Upper respiratory infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Leukopenia: significant reduction in white blood cells increasing infection risk.
  • Anemia: decreased red blood cell count leading to fatigue.
  • Severe infection: opportunistic infections requiring prompt medical attention.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Malignancy: increased long‑term risk of certain cancers.
  • Progressive multifocal leukoencephalopathy: rare but potentially fatal brain infection.

Precautions & Warnings

Before initiating Myfortic, clinicians should consider several safety measures.

  • Blood count monitoring: perform regular CBC to detect leukopenia or anemia.
  • Renal function assessment: adjust dosing in patients with impaired kidney function.
  • Live vaccine avoidance: do not administer live attenuated vaccines during therapy.
  • Pregnancy counseling: discuss potential risks and advise effective contraception.
  • Drug interaction review: evaluate concomitant immunosuppressants for additive effects.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Myfortic can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression may cause severe cytopenias.
  • Cyclosporine: increased mycophenolic acid exposure can heighten toxicity.
  • Tacrolimus: combined immunosuppression raises infection risk.

Moderate Interactions (Monitor Closely)

  • Rifampin: induces metabolism, reducing mycophenolic acid levels.
  • Antacids containing aluminum or magnesium: decrease absorption of the delayed‑release tablet.
  • Cholestyramine: binds drug in the gut, lowering systemic exposure.

Frequently Asked Questions

Myfortic is prescribed to prevent rejection of transplanted organs such as kidneys, hearts, and livers. It works by suppressing the immune system’s response to the graft, helping maintain long‑term transplant function.

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase, which is essential for guanosine nucleotide synthesis in lymphocytes. By blocking this pathway, the drug reduces the proliferation of T and B cells, thereby dampening the immune response that can lead to organ rejection.

The dosage of Myfortic is individualized by the prescribing clinician based on the type of transplant, patient weight, renal function, and concomitant immunosuppressants. Patients should follow the exact regimen provided by their healthcare professional.

The safety of Myfortic in pregnancy and lactation has not been definitively established. Women of childbearing potential should use effective contraception, and breastfeeding mothers should discuss potential risks with their physician before continuing therapy.

To request Myfortic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Myfortic (mycophenolic acid) is an antimetabolite that specifically targets lymphocyte proliferation, whereas calcineurin inhibitors like cyclosporine act on T‑cell activation pathways. Myfortic often offers a different side‑effect profile, with less nephrotoxicity but a higher incidence of gastrointestinal symptoms.

Myfortic tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability.

Myfortic is taken orally as a delayed‑release tablet. The tablet should be swallowed whole with water, preferably on an empty stomach, unless otherwise directed by the prescriber. Dosing times are usually coordinated with other immunosuppressants to optimize absorption.

Serious risks include severe infections due to immune suppression, leukopenia or anemia that can lead to bleeding or opportunistic infections, hepatic toxicity, and a potential increased risk of certain malignancies. Patients should be monitored regularly for these complications.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should also be avoided in individuals with active, uncontrolled infections or severe liver disease, and used with caution in pregnant or nursing women.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT